{
    "name": "perflutren",
    "comment": "Rx",
    "other_names": [
        "Definity RT",
        "Optison",
        "Definity"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/definity-rt-optison-perflutren-343761",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B (Definity); C (Optison)",
            "Lactation: use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Serious cardiopulmonary reactions, including death, can occur during or after use",
                "Most serious reactions occur within 30 minutes of administration",
                "Evaluate patients closely for contraindications",
                "Resuscitation equipment and personnel should be readily available"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to perflutren to lipid microsphere or components; Optison brand also warns for hypersensitivity to blood, blood products, or albumin"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "For IV use only; do not administer by intra-arterial injection",
                "Chronic pulmonary vascular disorder",
                "Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration (see Black Box Warnings)",
                "In patients with cardiac shunts, perflutren-containing microspheres can bypass the pulmonary particle-filtering mechanisms and directly enter the arterial circulation resulting in microvascular embolization that may cause occlusion and ischemia; assess patients with shunts for embolic phenomena following administration",
                "QT prolongation reported",
                "Therapy not recommended for use at mechanical indices > 0.8",
                "Assess patients for presence of conditions that preclude therapy administration; always have cardiopulmonary resuscitation personnel and equipment readily available prior to administration and monitor all patients for acute reactions"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Anaphylaxis, with manifestations that may include death, shock, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema; these reactions have occurred in patients with no prior exposure to perflutren-containing microsphere products",
                        "Product contains PEG; there may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG",
                        "Clinically assess patients for prior hypersensitivity reactions to products containing PEG, such as certain colonoscopy bowel preparations and laxatives",
                        "Always have cardiopulmonary resuscitation personnel and equipment readily available prior to product administration and monitor all patients for hypersensitivity reactions"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "QTc prolongation",
            "percent": "2.3-5.4"
        },
        {
            "name": "Headache",
            "percent": "1-4.3"
        },
        {
            "name": "Nausea",
            "percent": "1.1-3.6"
        },
        {
            "name": "vomiting",
            "percent": "0.62"
        },
        {
            "name": "Flushing",
            "percent": "5"
        },
        {
            "name": "warn sensation",
            "percent": "1.8"
        },
        {
            "name": "Dizziness",
            "percent": "1.4"
        },
        {
            "name": "Altered taste",
            "percent": "1.2"
        },
        {
            "name": "Chills",
            "percent": "0.8-1.1"
        },
        {
            "name": "fever",
            "percent": "1.1"
        },
        {
            "name": "Back",
            "percent": "1.1"
        },
        {
            "name": "renal pain",
            "percent": "1.1"
        },
        {
            "name": "Chest pain",
            "percent": "0.6-1.1"
        },
        {
            "name": "Dyspnea",
            "percent": "0.7"
        },
        {
            "name": "Flu",
            "percent": null
        },
        {
            "name": "like symptoms",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "weakness",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "Injection site discomfort",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Fatal cardiac arrests and other serious but nonfatal adverse reactions were uncommonly reported",
            "percent": null
        },
        {
            "name": "Most of these uncommon reactions included serious cardiopulmonary reactions and signs",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "cardiac or respiratory arrest",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "supraventricular and ventricular arrhythmias",
            "percent": null
        },
        {
            "name": "respiratory distress or decreased oxygenation",
            "percent": null
        },
        {
            "name": "Neurologic reactions",
            "percent": null
        },
        {
            "name": "loss of consciousness or convulsions",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        }
    ]
}